Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR1 Gene Amplification”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Ended earlyNCT02109016
What this trial is testing

Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Who this might be right for
Non-Small Cell Lung CancerSquamous Non-Small Cell Lung CancerNSCLC+6 more
Clovis Oncology, Inc. 18
Testing effectiveness (Phase 2)UnknownNCT04096417
What this trial is testing

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene Translocation+16 more
Academic and Community Cancer Research United 14
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Very early researchEnrolling By InvitationNCT07285434
What this trial is testing

Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Squamous Lung Cancer With FGFR1 AmplificationNon-Squamous Non Small Cell Lung Cancer
Biogenea Pharmaceuticals Ltd. 90
Testing effectiveness (Phase 2)Ended earlyNCT04024436
What this trial is testing

TAS-120 in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerFGFR 1 High AmplificationFGFR2 Amplification
Taiho Oncology, Inc. 64
Testing effectiveness (Phase 2)Study completedNCT01202591
What this trial is testing

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

Who this might be right for
FGFR Inhibition, Pharmacokinetics, BiomarkersER+ Breast Cancer
AstraZeneca 127
Testing effectiveness (Phase 2)Study completedNCT01948141
What this trial is testing

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Who this might be right for
Recurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage III Non-small Cell Lung Cancer+1 more
Roswell Park Cancer Institute 6
Large-scale testing (Phase 3)Study completedNCT02965378
What this trial is testing

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene Amplification+5 more
SWOG Cancer Research Network 43
Testing effectiveness (Phase 2)Ended earlyNCT02706691
What this trial is testing

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Who this might be right for
FGFR Gene AmplificationFGFR1 Gene AmplificationFGFR2 Gene Amplification+7 more
University of Chicago 1